Centiva Capital’s Cymabay Therapeutics CBAY Stock Holding History

Centiva Capital’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-23,300	Closed	-$255K	–	2214
2023 Q2	$255K	Buy	+23,300	New	+$217K	0.01%	1207

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Centiva Capital's CBAY Position: Q3 2023 in Review

Centiva Capital sold out of Cymabay Therapeutics (CBAY) in Q3 2023, closing a stake of 23,300 shares — an estimated $255K sold.

Centiva Capital first reported a position in CBAY in Q2 2023 and held it in 1 quarter. The position peaked at $255K in Q2 2023. 189 funds tracked by Wall St. Rank hold CBAY as of Q3 2023.

Centiva Capital reported no remaining Cymabay Therapeutics position as of Q3 2023 after selling out during the quarter.
Centiva Capital sold 23,300 Cymabay Therapeutics shares in Q3 2023, an estimated $255K.
Centiva Capital first reported a position in Cymabay Therapeutics in Q2 2023 and held it in 1 quarter.
Centiva Capital's Cymabay Therapeutics position peaked at $255K in Q2 2023.
189 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2023.

Based on Centiva Capital's 13F filing for Q3 2023, filed 14 Nov 2023.